Rocket Pharmaceuticals, Inc.
RCKT
$3.07
$0.082.68%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 1.16% | -1.12% | -7.79% | -6.00% | -6.38% |
| Total Depreciation and Amortization | 32.61% | 22.02% | 35.82% | 36.97% | 34.73% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -4.10% | 80.80% | 5.18% | 17.18% | 31.00% |
| Change in Net Operating Assets | -0.64% | -103.28% | 147.58% | -18.38% | 24.16% |
| Cash from Operations | 1.87% | -60.00% | 8.83% | -5.81% | 1.22% |
| Capital Expenditure | 82.11% | 93.35% | 65.89% | 53.14% | 32.50% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -255.58% | 72.41% | 52.16% | 62.93% | 209.98% |
| Cash from Investing | -265.65% | 73.10% | 63.55% | 78.25% | 195.41% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 46,664.45% | -99.91% | 740.66% | -93.55% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 46,664.45% | -99.91% | 740.66% | -93.55% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -451.53% | 157.75% | -85.05% | 117.10% | 72.82% |